drugset / Trial / NCT06670352
Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
RandomizedParallel-groupDouble-blindTreatment
Summary
Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN
Timeline
- Start
- 2024-10-12
- Primary completion
- 2025-12-20
- Completion
- 2026-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HSK39297 | Unknown | 50 mg | — |
| Subject | HSK39297 | Unknown | 100 mg | — |
| Subject | HSK39297 | Unknown | 200 mg | — |